DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Thai Participants With Chronic Non-Malignant Pain

Information source: Janssen-Cilag Ltd.,Thailand
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Pain

Intervention: TTS-Fentanyl (Drug); Morphine (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Janssen-Cilag Ltd.,Thailand

Official(s) and/or principal investigator(s):
Janssen-Cilag Ltd.,Thailand Clinical Trial, Study Director, Affiliation: Janssen-Cilag Ltd.,Thailand


The purpose of this study is to evaluate the efficacy and safety of Transdermal Therapeutic System (TTS)-fentanyl patch (transdermal patch containing a drug that is put on the skin so the drug will enter the body through the skin) in Thai participants with chronic (lasting a long time) non-malignant (non-cancerous) pain.

Clinical Details

Official title: Evaluation Study of Efficacy and Safety of TTS-Fentanyl in Chronic Non-Malignant Pain

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Change From Baseline in Pain Intensity Rating at Day 15

Change From Baseline in Pain Intensity Rating at Day 30

Secondary outcome:

Number of Participants With Investigator's Global Assessment

Number of Participants With Participant's Global Assessment

Detailed description: This is an open label (all people know the identity of the intervention), single arm study to assess the efficacy and safety of TTS-fentanyl in Thai participants with chronic non-malignant pain (except for headaches or central spinal cord mediated pain). The study will consist of 2 phases: stabilization phase (up to 7 days before starting the treatment) and treatment phase (30 days). The first patch will be applied by Investigator then by participants themselves until 30 days. All participants will start the treatment with patch releasing 25 micrograms per hour (mcg/h) of fentanyl . The patches will be replaced every 3 days. On Day 3, and every 3 days thereafter, the TTS-fentanyl dose can be titrated (slow increase in drug dosage, guided by participant's responses) as per participant's need. The duration of the treatment will be 30 days after first patch application. The dose of TTS-fentanyl can be slowly increased if needed, by 25 mcg/h to achieve adequate pain control. No increase in TTS-fentanyl dose will be performed within the 72-hour dosing interval. Participants will be allowed the use of oral morphine syrup for the duration of TTS-fentanyl treatment to enable appropriate TTS-fentanyl dose titration. Primary efficacy assessment will be pain control rated by participants. Assessment time points will be Day 0 (Baseline), Day 15 and Day 30 (trial end). At the end of study, global preference on efficacy, side effects and overall satisfaction will also be rated by Investigator and participants. Participants' safety will be monitored throughout the study.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Participants with chronic non-malignant pain (of any etiology except for headaches or

central spinal cord mediated pain) with moderate (medium level of seriousness) to severe (very serious, life threatening) pain that requires treatment with a potent opioid

- Participants must also be currently treated with short or long acting opioid

medications other than Transdermal Therapeutic System (TTS)-fentanyl at a dose less than or equal to 134 milligram per day (mg/day) of oral morphine (or an equianalgesic dose of another opioid), participants may have been treated with TTS-fentanyl in the past

- Participants who had side effects after receiving Non Steroidal Anti-inflammatory

Drugs (NSAIDs)

- Participants who failed from other treatments such as operation or lack of efficacy

of current treatment

- Participants with spinal cord stimulators may enroll, provided that they turn the

spinal cord stimulator off for the duration of the trial, or leave it continually on for the duration of the trial Exclusion Criteria:

- History of allergy, hypersensitivity, or lack of ability to tolerate fentanyl

- Skin disease that precludes the use of the transdermal system or which could affect

the absorption of fentanyl or local tolerability

- History or suspicion of alcohol or drug abuse within the past 5 years

- History of narcotic (strong habit-forming drug that stops pain and depresses the

central nervous system) therapy

- Pregnancy or breast-feeding female

Locations and Contacts

Bangkok, Thailand

Department of Anesthesia, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

Additional Information

Starting date: April 2004
Last updated: April 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017